Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Prognostic Discrimination of Children and Adolescents with Chronic Myeloid Leukemia Based on the EUTOS Long Term Survival (ELTS) Score

Frédéric Millot, MD, Joelle Guilhot, PhD, Meinolf Suttorp, MD PhD, Adalet Meral Güneş, MD, Petr Sedlacek, MD, Evelina S De Bont, MD PhD, Chi Kong Li, MBBS, MD, Krzysztof Kalwak, MD, Birgitte Lausen, Srdjana Culic, MD, Barbara De Moerloose, MD, Andrea Biondi, MD, Andre Baruchel, MD PhD

Blood (2016) 128 (22): 626.

https://doi.org/10.1182/blood.V128.22.626.626

Published: 2016

Journal Articles

Safety and Pharmacokinetics Of Clofarabine In Combination With High-Dose Cytarabine and Liposomal Daunorubicin In Pediatric AML: Results Of a Phase 1 Combination Study By The ITCC Consortium

Christian M. Zwaan, Michael Dworzak, Thomas Klingebiel, MD, Claudia Rossig, MD, Guy Leverger, MD, Jan Stary, Evelina S. De Bont, MD, PhD, Satianand Ramnarain, MSc, Yves Bertrand, MD, Essam A Ghazaly, MD, Dirk Reinhardt

Blood (2013) 122 (21): 2693.

https://doi.org/10.1182/blood.V122.21.2693.2693

Published: 2013

Journal Articles

Insights in Dynamic Kinome Reprogramming As a Consequence of MEK Inhibition in MLL-Rearranged AML.

Kim R Kampen, Arja ter Elst, PhD, Sander H Diks, PhD, Frank JG Scherpen, Valerie De Haas, Maikel P Peppelenbosch, Evelina S. De Bont, MD, PhD

Blood (2012) 120 (21): 2338.

https://doi.org/10.1182/blood.V120.21.2338.2338

Published: 2012

Journal Articles

Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.

Costa Bachas, MSc, Gerrit Jan Schuurhuis, PhD, Dirk Reinhardt, MD, Ursula Creutzig, MD, PhD, Zinia J. Kwidama, BSc, C. Michel Zwaan, MD, PhD, Marry M. van den Heuvel-Eibrink, Evelina S De Bont, MD, PhD, Sara Elitzur, MD, Carmelo Rizzari, MD, PhD, Valérie de Haas, MD, PhD, Martin Zimmermann, Jacqueline Cloos, PhD, Gertjan J.L. Kaspers, MD, PhD

Blood (2012) 120 (21): 2480.

https://doi.org/10.1182/blood.V120.21.2480.2480

Published: 2012

Journal Articles

Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML

Costa Bachas, MSc, Gerrit Jan Schuurhuis, PhD, C. Michel Zwaan, MD, PhD, Marry M. van den Heuvel-Eibrink, Monique L. Den Boer, PhD, Zinia J. Kwidama, BSc, Evelina S. De Bont, MD, PhD, Dirk Reinhardt, MD, Ursula Creutzig, MD, PhD, Valérie de Haas, MD, PhD, Yehuda Assaraf, PhD, Gertjan J.L. Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2012) 120 (21): 283.

https://doi.org/10.1182/blood.V120.21.283.283

Published: 2012

Journal Articles

Activation of the EfnB1/EphB1 Forward Signaling Promotes Cell Cycle Arrest in Acute Myeloid Leukemia Cells

Kim R Kampen, Arja ter Elst, PhD, Evelina S. De Bont, MD, PhD

Blood (2012) 120 (21): 4719.

https://doi.org/10.1182/blood.V120.21.4719.4719

Published: 2012

Journal Articles

Cyclic-AMP Responsive Element Binding Protein 1 (CREB) As a New Potential Druggable Target in Pediatric Acute Lymphoblastic Leukemia

Naomi E van der Sligte, Arja ter Elst, PhD, Kim R Kampen, Frank JG Scherpen, Hendrik Mulder, Sander H Diks, PhD, Frank N. van Leeuwen, PhD, Evelina S. De Bont, MD, PhD

Blood (2011) 118 (21): 1368.

https://doi.org/10.1182/blood.V118.21.1368.1368

Published: 2011

Journal Articles

EphrinB1 Activation As a Potential New Treatment Option in AML

Arja ter Elst, PhD, Kim R Kampen, Sander H Diks, PhD, Steven M. Kornblau, MD, Guillermo Garcia-Manero, Evelina S. De Bont, MD, PhD

Blood (2011) 118 (21): 5235.

https://doi.org/10.1182/blood.V118.21.5235.5235

Published: 2011

Journal Articles

Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab

Alida C. Weidenaar, Arja ter Elst, PhD, Cees AGM van Montfort, PhD, Tiny G.J. Meeuwsen-de Boer, Stefano Rosati, MD, Mario Bargetzi, MD, Carlos Graux, MD, PhD, Alois Gratwohl, MD, PhD, Bob Lowenberg, MD, PhD, Gert Ossenkoppele, MD, PhD, Evelina S. De Bont, MD, PhD

Blood (2011) 118 (21): 1555.

https://doi.org/10.1182/blood.V118.21.1555.1555

Published: 2011

Journal Articles

Epidermal Growth Factor Receptor Expression and Activity In Acute Myeloid Leukemia

Arja ter Elst, Steven M. Kornblau, MD, Frank jg Scherpen, Yi Hua Qiu, MD, Nianxiang Zhang, Kevin R Coombes, Evelina S. De Bont, MD, PhD

Blood (2010) 116 (21): 3144.

https://doi.org/10.1182/blood.V116.21.3144.3144

Published: 2010

Journal Articles

Targeting Multiple Active Kinase Pathways In 11q23 Translocated Pediatric Acute Myeloid Leukemia Using a VEGFR2 Antibody Together with a MEK Inhibitor.

Arja ter Elst, Kim R Kampen, Sander H Diks, Frank JG Scherpen, Válerie de Haas, MD, PhD, Maikel P Peppelenbosch, Evelina S. De Bont, MD, PhD

Blood (2010) 116 (21): 3626.

https://doi.org/10.1182/blood.V116.21.3626.3626

Published: 2010

Journal Articles

High IGSF4 expression In Pediatric Acute Monoblastic Leukemia with t(9;11)

Eva A Coenen, MD, Jenny Kuipers, Brian V Balgobind, Jan Stary, Andre Baruchel, Valerie de Haas, Evelina S. De Bont, MD, PhD, Dirk Reinhardt, MD, PhD, Gertjan J. Kaspers, MD, PhD, Jacqueline Cloos, Astrid Danen-van Oorschot, Monique L. Den Boer, Rolf Marschalek, Claus Meyer, Rob Pieters, MD, PhD, Christian M. Zwaan, MD, PhD, Marry van den Heuvel-Eibrink

Blood (2010) 116 (21): 3614.

https://doi.org/10.1182/blood.V116.21.3614.3614

Published: 2010

Journal Articles

Gene Expression Profiling In Leukemic Stem Cell-Enriched AML CD34 + Cell Fraction Identifies Target Genes That Predict Prognosis In Normal Karyotype AML

Carolien M Woolthuis, Hendrik JM de Jonge, Annet Z Vos, Andre B Mulder, MD, Eva van den Berg, P.M. Kluin, MD, PhD, Karen van der Weide, Evelina S. De Bont, MD, PhD, Geert A Huls, MD, PhD, Edo Vellenga, MD, PhD, Jan J. Schuringa, PhD

Blood (2010) 116 (21): 952.

https://doi.org/10.1182/blood.V116.21.952.952

Published: 2010

Journal Articles

AML1/RUNX1, One of the Most Common Targets of Aberration in Acute Myeloid Leukemia as a Transcriptional Regulator of Vascular Endothelial Growth Factor (VEGFA).

Arja ter Elst, PhD, Bin Ma, Frank Scherpen, Bart-Jan A.T. Wierenga, Jan Jacob Schuringa, PhD, Jenny Douwes, Willem A. Kamps, MD/PhD, Evelina S. de Bont, MD/PhD

Blood (2007) 110 (11): 1618.

https://doi.org/10.1182/blood.V110.11.1618.1618

Published: 2007

Journal Articles

Addition of PTK787/ZK 222584 Can Lower the Dosage of Amsacrine To Achieve Equal Amounts of AML Cell Death.

Alida C. Weidenaar, Hendrik J.M. de Jonge, Vaclav Fidler, PhD, Arja ter Elst, PhD, Tiny Meeuwsen, Jenny Douwes, Jessica C.A. Bouma, PhD, Karel Hählen, MD/PhD, Willem A. Kamps, MD/PhD, Evelina S. de Bont, MD/PhD

Blood (2007) 110 (11): 4199.

https://doi.org/10.1182/blood.V110.11.4199.4199

Published: 2007

NARROW

Prognostic Discrimination of Children and Adolescents with Chronic Myeloid Leukemia Based on the EUTOS Long Term Survival (ELTS) Score

Safety and Pharmacokinetics Of Clofarabine In Combination With High-Dose Cytarabine and Liposomal Daunorubicin In Pediatric AML: Results Of a Phase 1 Combination Study By The ITCC Consortium

Insights in Dynamic Kinome Reprogramming As a Consequence of MEK Inhibition in MLL-Rearranged AML.

Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.

Harnessing Gene Expression Profiles for the Identification of Drug Resistance Genes in Pediatric AML

Activation of the EfnB1/EphB1 Forward Signaling Promotes Cell Cycle Arrest in Acute Myeloid Leukemia Cells

Cyclic-AMP Responsive Element Binding Protein 1 (CREB) As a New Potential Druggable Target in Pediatric Acute Lymphoblastic Leukemia

EphrinB1 Activation As a Potential New Treatment Option in AML

Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab

Epidermal Growth Factor Receptor Expression and Activity In Acute Myeloid Leukemia

Targeting Multiple Active Kinase Pathways In 11q23 Translocated Pediatric Acute Myeloid Leukemia Using a VEGFR2 Antibody Together with a MEK Inhibitor.

High IGSF4 expression In Pediatric Acute Monoblastic Leukemia with t(9;11)

Gene Expression Profiling In Leukemic Stem Cell-Enriched AML CD34 + Cell Fraction Identifies Target Genes That Predict Prognosis In Normal Karyotype AML

AML1/RUNX1, One of the Most Common Targets of Aberration in Acute Myeloid Leukemia as a Transcriptional Regulator of Vascular Endothelial Growth Factor (VEGFA).

Addition of PTK787/ZK 222584 Can Lower the Dosage of Amsacrine To Achieve Equal Amounts of AML Cell Death.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only